May 21, 2022
Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.
April 26, 2022
Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.
April 14, 2022
Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.
April 12, 2022
Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.
April 11, 2022
Updated data from the phase 1/2 CodeBreaK 100 trial of sotorasib provide the longest follow-up of a KRAS G12C inhibitor in non–small cell lung cancer.
March 20, 2022
The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.
February 19, 2022
Results of the phase 3 PROpel trial presented at 2022 ASCO GU indicate a benefit of olaparib-based therapy for patients with metastatic castration-resistant prostate cancer receiving treatment in the frontline setting.
February 18, 2022
Frontline avelumab plus best supportive care as maintenance showed an improvement in overall survival vs best supportive care alone in patients with advanced urothelial cancer treated after chemotherapy.
January 20, 2022
Patients saw an improvement in overall survival when given fam-trastuzumab deruxtecan-nxki to treat HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
December 14, 2021
Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.